Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas.

The pharmacogenetics of cancer treatment has been aimed at identifying genetic components of interindividual variability in patients' response to cancer chemotherapy and toxicity. This, in turn, will establish an individually based treatment, and also elucidate the molecular basis of the treatment regimen for further improvements. Brain cancer is an instructive example for the potential contributions of pharmacogenomics to improved treatment in the 21st century. Patients with oligodendrogliomas have benefited from phamacogenomics, as there is a clear relationship between response to chemotherapy and chromosomal profile. Drug efficacy, safety and response could be improved by using pharmacogenomics to identify genetic markers that differentiate responder from nonresponder patient groups, as well as identifying patients likely to develop adverse drug reactions. This review will focus on how pharmacogenomics by microarray studies may lead to much more accurate tumor classification, drug and biomarker discovery, and drug efficacy testing. We will discuss relevant scientific advances in pharmacogenetics for more personalized chemotherapy.

[1]  M. Gilbert,et al.  Molecularly targeted therapies for malignant gliomas: advances and challenges , 2007, Expert review of anticancer therapy.

[2]  Elias S. J. Arnér,et al.  Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. , 1994, Advances in enzyme regulation.

[3]  Clive R. Taylor,et al.  Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Recht,et al.  Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas , 2006 .

[5]  M. Gilbert,et al.  New molecular targets in malignant gliomas , 2007, Current opinion in neurology.

[6]  Tian-Li Wang,et al.  Apply innovative technologies to explore cancer genome , 2005, Current opinion in oncology.

[7]  Michael Weller,et al.  Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.

[8]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[9]  P. Goodfellow,et al.  DNA microarrays in drug discovery and development , 1999, Nature Genetics.

[10]  P. Mullan,et al.  Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling. , 2001, Biochemical Society transactions.

[11]  K. Lamborn,et al.  Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. , 2007, International journal of radiation oncology, biology, physics.

[12]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[13]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[14]  H. McLeod,et al.  Pharmacogenetics goes 3D , 2005, Nature Genetics.

[15]  P. Wen,et al.  Glioma Therapy in Adults , 2006, The neurologist.

[16]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[17]  B. Meshkin,et al.  Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. , 2005, Mutation research.

[18]  S. Peller.  Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. , 1998, Seminars in cancer biology.

[19]  H. Groen,et al.  Genetic factors influencing Pyrimidine-antagonist chemotherapy , 2005, The Pharmacogenomics Journal.

[20]  D. Arango,et al.  Microarray analysis in the clinical management of cancer. , 2003, Hematology/oncology clinics of North America.

[21]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[22]  R. Puri,et al.  Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy* , 2006, Technology in cancer research & treatment.

[23]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[24]  N. Colburn,et al.  MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene , 2008, Oncogene.

[25]  Tim Hui-Ming Huang,et al.  Oligonucleotide‐based microarray for DNA methylation analysis: Principles and applications , 2003, Journal of cellular biochemistry.

[26]  Shuichi Tsutsumi,et al.  Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p , 2002, Oncogene.

[27]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[28]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[29]  W. Zumkeller.  IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? , 2001, Molecular pathology : MP.

[30]  D. Louis,et al.  Chemosensitive gliomas in adults: which ones and why? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Santosh Kesari,et al.  Therapy for recurrent malignant glioma in adults , 2004, Expert review of anticancer therapy.

[32]  Mitchel S Berger,et al.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[35]  S. Ozawa,et al.  Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[36]  S. Horvath,et al.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.

[37]  G. Calin,et al.  MicroRNA Involvement in Brain Tumors: From Bench to Bedside , 2008, Brain pathology.

[38]  F. Naour.  Contribution of proteomics to tumor immunology , 2001 .

[39]  D. Bigner,et al.  Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients , 2007, Expert review of anticancer therapy.

[40]  Webster K. Cavenee,et al.  Aberrant methylation of genes in low-grade astrocytomas , 2006, Brain Tumor Pathology.

[41]  L L Hsiao,et al.  Prospective use of DNA microarrays for evaluating renal function and disease. , 2000, Current opinion in nephrology and hypertension.

[42]  M. Glantz,et al.  Chemotherapeutic options for primary brain tumors , 2006, Current treatment options in oncology.

[43]  A. Karlsson,et al.  Human deoxycytidine kinase is located in the cell nucleus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Alonso,et al.  CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours , 2003, British Journal of Cancer.

[45]  C. Bueso-Ramos,et al.  Pathologic diagnosis of acute lymphocytic leukemia. , 2000, Hematology/oncology clinics of North America.

[46]  Lisa Meyer,et al.  Immobilized probe and glass surface chemistry as variables in microarray fabrication , 2004, BMC Genomics.

[47]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Bednár.  DNA microarray technology and application. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[49]  M Schena,et al.  Microarrays: biotechnology's discovery platform for functional genomics. , 1998, Trends in biotechnology.

[50]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[51]  E. Bandrés,et al.  Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression , 2005, Journal of Neuro-Oncology.

[52]  E. Reyt,et al.  Chronic hypoxia protects against gamma-irradiation-induced apoptosis by inducing bcl-2 up-regulation and inhibiting mitochondrial translocation and conformational change of bax protein. , 2003, International journal of oncology.

[53]  Yunqing Li,et al.  microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. , 2008, Cancer research.

[54]  A. Matsuda,et al.  Deletion Mutants of Human Deoxycytidine Kinase mRNA in Cells Resistant to Antitumor Cytosine Nucleosides , 2001, Japanese journal of cancer research : Gann.

[55]  Gianluca Bontempi,et al.  Evidence of galectin-1 involvement in glioma chemoresistance. , 2008, Toxicology and applied pharmacology.

[56]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[57]  R. Wooster,et al.  Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. , 2001, Biochemical pharmacology.

[58]  P. Burger,et al.  Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss , 2006, Journal of neuropathology and experimental neurology.

[59]  T. Suzuki,et al.  Pharmacogenomics and schizophrenia. , 2000, European journal of pharmacology.

[60]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[61]  D. Cavalieri,et al.  Emerging Treatments and Gene Expression Profiling in High-Risk Medulloblastoma , 2007, Paediatric drugs.

[62]  T. Cloughesy,et al.  PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors , 2007, Clinical Cancer Research.

[63]  M. Gilbert.  Designing clinical trials for brain tumors: The next generation , 2007, Current oncology reports.

[64]  L. Recht,et al.  High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. , 2005, Cancer research.

[65]  J. Baselga.  Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.

[66]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[67]  O. Wiestler,et al.  Epigenetic Silencing of the Protocadherin Family Member PCDH-γ-All in Astrocytomas , 2005 .

[68]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[69]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[70]  Konstantin Khrapko,et al.  A microRNA array reveals extensive regulation of microRNAs during brain development. , 2003, RNA.

[71]  Miguel Alaminos,et al.  EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.

[72]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  G Powathil,et al.  Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy , 2007, Physics in medicine and biology.

[74]  Kennedy Gc.  The impact of genomics on therapeutic drug development. , 2000 .

[75]  David M Sabatini,et al.  Cell-biological applications of transfected-cell microarrays. , 2002, Trends in cell biology.

[76]  R. Mahesparan,et al.  Biological Mechanisms of Glioma Invasion and Potential Therapeutic Targets , 2001, Journal of Neuro-Oncology.

[77]  B. Haab,et al.  Advances in protein microarray technology for protein expression and interaction profiling. , 2001, Current opinion in drug discovery & development.

[78]  J. Lilleyman,et al.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.

[79]  T C Yih,et al.  Engineered nanoparticles as precise drug delivery systems , 2006, Journal of cellular biochemistry.

[80]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Polli,et al.  Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. , 2000, Pharmacogenetics.